Targeted drug study for advanced cancers with genetic changes
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that is getting worse (progressing) now.
- You have measurable or evaluable tumors your doctors can track on scans (and for some parts, not previously irradiated areas).
- Your body is healthy enough for study treatment based on blood counts and organ function tests.
- Your cancer must match one of the study’s specific tumor types and genetic or biomarker patterns (for example BRCA1/2, PALB2, RAD51C, RAD51D changes; HER2-negative breast; or IDH1/2-mutant glioma depending on the module).
- You must be able to follow eating rules and time restrictions for the study drug (high-fat meal/fasting rules apply in Module 1).
- If your part of the study involves pregnancy-risk participants, you must use required birth control and have negative pregnancy tests as scheduled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
Hear when a new Advanced Solid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.